TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Vitamin D Supplementation in Children With Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* children with SCD (HbSS, hemoglobin sickle beta zero (HbSβ0) thalassemia genotype), aged ≤ 18 years old, male or female study participants who were at a steady state (≥ one month from blood transfusion and ≥ 14 days from any acute sickle complication as hospitalization for Vaso occlusive crisis (VOC) or acute chest syndrome (ACS)), stable Hb level near their usual baseline and stable dose of Hydroxyurea (HÚ) mg/kg for at least 90 days prior to enrollment.~* A control group of 42 healthy age and sex-matching children~Exclusion Criteria:~* SCD patients who are on chronic blood transfusion therapy~* Comorbid chronic conditions~* Use of medications known to interfere with calcium or vitamin D absorption or metabolism~* Known hypercalcemia or vitamin D hypersensitivity~* Use of vitamin D therapy to treat vitamin D deficiency or rickets~* Urolithiasis, liver or renal impairment, and malabsorption disorders.~* Obese children with body mass index (BMI) \> 85th percentile for age and sex

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Oral vitamin D3 (Type: EXPERIMENTAL): Monthly oral vitamin D3 dose (100,000 IU,150,000 IU, and 200,000 IU)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Fibrin Patch Soft Tissue Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects \>= 18 years of age, requiring non-emergent, open, abdominal, retroperitoneal, pelvic or thoracic (non-cardiac) surgical procedures~* Presence of an appropriate soft tissue Target Bleeding Site (TBS) as identified intraoperatively by the surgeon~* Subjects must be willing to participate in the study, and provide written informed consent~Exclusion Criteria:~* Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure~* Subject with TBS within an actively infected field~* Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine~* Subjects with known intolerance to blood products or to one of the components of the study product~* Subjects unwilling to receive blood products~* Subjects with immunodeficiency diseases (including known HIV)~* Subjects who are known, current alcohol and / or drug abusers~* Subjects who have participated in another investigational drug or device research study within 30 days of enrollment~* Female subjects who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): SURGICEL™ Absorbable Hemostat

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Femoral Blockade and Low-dose Spinal Anesthesia in Outpatient Knee Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II patients aged between 25-65 undergoing arthroscopic meniscus repair~Exclusion Criteria:~* Contraindications to regional anesthesia (coagulopathy, severe aortic stenosis, sever mitral stenosis, increased intracranial pressure, severe hypovolemia, presence of infection on the site of injection)~* Presence of previous spinal surgery~* Presence of diabetes mellitus~* Presence of neurological disturbance~* Uncooperated patients, patients not accepting to participate the study~* Allergy to study drugs~* ASA II-IV patients, BMI \>38, Height \< 150 cm and \>190 cm

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group F (Type: ACTIVE_COMPARATOR): Ultrasound-guided femoral blockade with 15 mL of bupivacaine 0.5% diluted in 15 mL saline was performed in supine position. Then the patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 1 mL (5 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.~.
- Group S (Type: ACTIVE_COMPARATOR): The patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 2 mL (10 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Males or females between the ages of 18 and 65 suffering from seasonal allergic rhinitis provoked by ragweed pollen.~* Having a 2-year history of seasonal allergic rhinitis with positive skin prick test to ragweed allergen at screening with a wheal diameter at least 3 mm larger than that produced by the negative control.~* Subjects with antecedents of allergic seasonal allergic rhinitis symptom aggravation when exposed to pollen and air pollutants (i.e., cleaning products, diesel, paints).~* Subjects having a total nasal symptom score ≥3 in Period 1 (Visit 2).~Exclusion criteria:~* History of anaphylaxis to ragweed pollen.~* History of asthma. Mild asthmatics treated only with pro re nata short-acting beta2-agonists, 2 doses or less per week can be enrolled.~* History of chronic sinusitis.~* History of systemic disease affecting the immune system.~* Evidence of any active or suspected bacterial, viral, fungal or parasitic infections within 30 days prior to allergen challenge.~* Any history of Grade 4 anaphylaxis due to any cause as defined by the Common Terminology Criteria for Adverse Event grading criteria (Life threatening consequences: urgent intervention indicated).~* Presence or history of drug hypersensitivity to fexofenadine.~* Subjects receiving build-up injections of pollen allergen immunotherapy (those on stable maintenance dosing can be included).~* Subjects taking any forbidden treatments/nutriments.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fexofenadine (Type: EXPERIMENTAL): Fexofenadine, single administration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, single administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and Females~* Age 6 months to 17 years~* Scheduled for elective scoliosis surgery or major craniofacial surgery~* Written informed consent has been obtained~* Intraoperative hypofibrinogenemia according to definition of treatment groups~Exclusion Criteria:~* Preexisting congenital or acquired coagulation disorder~* Medical history of estimated increased bleeding tendency~* Ongoing coagulation therapy~* Clinical signs or diagnosis of acute thromboembolism~* Intolerance of study drug~* Participation at another clinical trial~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Fibrinogen if FibTEM < 8 mm (Type: ACTIVE_COMPARATOR): Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF \< 8 mm
- Fibrinogen if FibTEM < 13 mm (Type: EXPERIMENTAL): Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF \< 13 mm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-menopausal, aged 18-42 old at time of consent~* At least one cycle without fertility medication prior to screening~* Tubal, idiopathic, male factor, ovulatory dysfunction or endometriosis- linked infertility~* Semen analysis (frozen sperm, including donor sperm, may be used, as long as testing done at time of freezing meets standard criteria)~* Others as indicated by FDA-approved protocol~Exclusion Criteria:~* Any contraindication to progesterone therapy~* BMI \> 38 kg/m2~* Clinically significant gynecologic pathology (for example: submucosal fibroids, abnormal uterine cavity, or others)~* History of more than 1 failed fresh IVF cycles~* More than 2 consecutive clinical miscarriages (gestational sac observed on ultrasound)~* Others as indicated by FDA-approved protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Selected Inclusion Criteria:~1. Adult male and female, HIV-1-infected patients 18 years old and older.~2. Body mass index (BMI) 18 to \< 35 kg/m2.~3. Antiretroviral treatment-naïve. Treatment-naïve is defined as:~   * No prior nonnucleoside reverse transcriptase inhibitor, other than in women who received a single dose of perinatal nevirapine who have no K103 viral mutation.~  * No prior CCR5 antagonist therapy.~  * No more than 10 days of any other prior antiretroviral therapy.~4. HIV-1 CCR5-tropic-only virus.~5. Plasma HIV-1 RNA level \>/=1,000 copies/mL at first Screening.~6. CD4 cell count \>/=250 cells/mm3 at first Screening.~Selected Exclusion Criteria:~1. Presence of CXCR4- or dual/mixed-tropic HIV-1 virus.~2. Presence of primary resistance mutations or phenotypic resistance to TDF, FTC, or EFV and/or mutations associated with multidrug nucleoside/nucleotide resistance.~3. An active CDC category C disease (except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial).~4. Any historical CD4 count \< 200 cells/mm3.~5. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value Grade \> 2 or total bilirubin greater than the upper limit of normal (ULN).~6. History of HIV-2, hepatitis B and/or C, cirrhosis of the liver, or any known active or chronic liver disease. Hepatitis B vaccinated patients are eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CVC 100 mg + Truvada (Type: EXPERIMENTAL): None
- CVC 200 mg + Truvada (Type: EXPERIMENTAL): None
- Sustiva + Truvada (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Skin Prep to Reduce Postoperative Shoulder Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18~* Indicated for shoulder surgery~Exclusion Criteria:~* History of previous shoulder infection~* Allergy to Chlorhexidine or benzoyl peroxide~* Current use of anti-acne medicine around the shoulder~* Patient is pregnant or concerned about pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorhexidine (Type: ACTIVE_COMPARATOR): A preoperative Chlorhexidine gluconate solution 4.0% (i.e Hibiclens)
- Benzoyl Peroxide (Type: EXPERIMENTAL): A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 2-18 years of age.~* Have a diagnosis of Pompe, as defined by protein assay, DNA sequence of the acid alpha-glucosidase gene and clinical symptoms of the disease.~* Using assisted ventilation at baseline. Mechanical Ventilation is defined as any use of ventilation support, (including but not limited to BiPAP, CPAP), a minimum of 1 hours per day.~* Willing to discontinue aspirin, aspirin-containing products and other drugs that may alter platelet function, 7 days prior to dosing, resuming 24 hours after the dose has been administered.~Exclusion Criteria:~The subject must not:~* Have required acute, as distinguished from long-term, maintenance or chronic suppressive, oral or intravenous antibiotic therapy for a respiratory infection within 15 days prior to baseline screening.~* Have required oral or systemic corticosteroids within the last 15 days prior to baseline screening.~* Have a platelet count less than 75,000/ cu mm.~* Have an INR greater than 1.3.~* Serological evidence of hepatitis B, hepatitis C, or HIV positive.~* Be currently or within the past 30 days participating in any other research protocol involving investigational agents or therapies.~* Have received gene transfer agents within the past 6 months.~* Have history of platelet dysfunction, evidence of abnormal platelet function at screening or history of recent use of drugs that may alter platelet function which the subject is unable/unwilling to discontinue for study agent administration.~* Have any other concurrent condition which, in the opinion of the investigator, would make the subject unsuitable for the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- rAAV1-CMV-GAA administration-cohort 1 (Type: EXPERIMENTAL): rAAV1-CMV-GAA (study agent) Administration: 1.0 x 10e12 vector genomes. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
- rAAV1-CMV-GAA administration-cohort 2 (Type: EXPERIMENTAL): rAAV1-CMV-GAA (study agent) Administration: 5.0 x 10e12 vector genomes Cohort 2 = 6 subjects. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with type 2 diabetes~* Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment~Exclusion Criteria:~* Hypersensitivity (allergy) to liraglutide or to any of the excipients~* Patient is participating in a clinical trial at the inclusion~* Type 1 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron Deficiency (ID) in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infants aged 22-26 months~* living usually in France~* written agreement of one parent or the holder of parental authority~* followed-up by a liberal paediatrician~* with social coverage~Exclusion Criteria:~* chronic disease known at inclusion that might affect iron metabolism or reserves : blood transfusion since birth, celiac disease, chronic inflammatory disease, including of the intestines, cystic fibrosis, other enteropathy, enteral nutrition for more than 15 days in the past 6 months, chronic hemolytic diseases, chronic kidney disease, hemophilia, or chronic bleeding, such as ENT or gastrointestinal, hemochromatosis, any malignant condition, or lead poisoning)~* participation to another study

- Gender: ALL
- Minimum Age: 22 Months
- Maximum Age: 26 Months
- Healthy Volunteers: f

Study Arms:
- infants followed by pediatrician (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of symptomatic multiple myeloma as defined by International Myeloma Working Group (IMWGURC).~* Phase 1: Relapsed or relapsed/refractory myeloma after at least 1 previous treatments and with a life expectancy of more than 3 months.~* Phase 2: Measurable (as defined by IMWGURC) disease after at least 1 previous treatment.~Exclusion Criteria:~* History of allogeneic stem cell transplant.~* Phase 2 only: Prior bortezomib therapy will only be allowed if there was a demonstrated positive response, and disease progression occurred off therapy.~* Must have not experienced significant blood level changes, e.g. very low platelets, while on previous bortezomib therapy~* Prior radiation therapy to \> 25% of the bone marrow (whole pelvis is 25%).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed Type 2 Diabetes Mellitus (T2DM) for at least 3 months prior screening~* On a stable treatment regimen for at least 2 months prior screening~* Medically stable on the basis of physical examination, medical history, and clinical laboratory tests performed at screening and 2 days before administration of the study medication~* Fasting plasma glucose (FPG) concentrations between 140 mg/dL and 270 mg/dL on 2 days before administration of the study medication~* Agrees to protocol-defined use of effective contraception~Exclusion Criteria:~* History of other types of diabetes and complications or secondary forms of diabetes~* History of eating disorder or recent significant changes in body weight (ie, more or equal to 5 percent over 3 months prior to screening) due to dieting or nutritional treatments~* Taking antihyperglycemic agents (insulin, exenatide, and liraglutide) within 6 months or thiazolidinedione within 3 months of 2 days before administration of the study medication~* Clinically significant abnormal electrocardiogram~* History of, or currently active, significant illness or medical disorders, retinal disease, tuberculosis~* Clinically important serious infection, positive for serology at screening (hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus antibodies)

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-41443532 250 mg (Type: EXPERIMENTAL): Participants will receive JNJ-41443532 250 mg in morning and evening for 28 days.
- JNJ-41443532 1000 mg (Type: EXPERIMENTAL): Participants will receive JNJ-41443532 1000 mg (4 X 250 mg) in morning and evening for 28 days.
- Pioglitazone (Type: ACTIVE_COMPARATOR): Participants will receive pioglitazone 30 mg in morning for 28 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive matching placebo for JNJ-41443532 and pioglitazone for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete